|
|
|
|
Diabetes and Cardiovascular Disease: Time To Act!
|
|
|
|
Glucose Toxicity
|
|
|
|
UKPDS:Microvascular Complications, MI, and HbA1c
|
|
|
|
UKPDS Endpoints by Glucose Treatment Group
|
|
|
|
|
|
|
Patho-physiology of Type 2 diabetes
|
|
|
|
Free Fatty Acids: Insulin Resistance, IGT and Type 2 NIDDM
|
|
|
|
Pioglitazone 30-45 mg/d Reduces Plasma Glucose
|
|
|
|
Time to Primary Composite Endpoint
|
|
|
|
PROactive Total Events
|
|
|
|
Time to : Death, MI ( excluding silent ) or Stroke
|
|
|
|
|
Time to Fatal/Non-fatal MI
|
|
|
|
|
|
|
|
CHICAGO: Glycaemic Control Change in HbA1c
|
|
|
|
CHICAGO: Treatment effect on posterior wall mean CIMT
|
|
|
|
|
|
PROactive Metabolic Effects of Pioglitazone
|
|
|
|
|
|
CHF
|
|
|
|
|
|
|
|
|
|
|
|
|
presentation (PPTX 3.4MB)
Share this page with your colleagues and friends: